Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25

International Journal of Oncology

Volumn 37, Issue 6, 2010, Pages 1439-1452

  Fournier, Philippe ^a   Aigner, Maximilian ^a   Schirrmacher, Volker ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Center of Immunology and Oncology (IOZK)   (Germany)

Author keywords

Antitumor; Array; Bispecific antibodies; Costimulation (signal 2); Gene chip; IL 2; Signal 1; T cell activation and proliferation; Vaccination

Indexed keywords

BSHN INTERLEUKIN 2; CD3 ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 2; TRANSCRIPTOME; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CYTOKINE PRODUCTION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIGENS, CD3; CANCER VACCINES; CHO CELLS; COCULTURE TECHNIQUES; CRICETINAE; CRICETULUS; CYTOKINES; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; PROTEIN BINDING; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 78649912170     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000796     Document Type: Article

References (51)

1. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V and Umansky V: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7: 452-458, 2001. (Pubitemid 32298548)
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006.
3. Seliger B, Maeurer MJ and Ferrone S: Antigen-processing machinery breakdown and tumor growth. Immunol Today 21: 455-464, 2000.
4. Hicklin DJ, Marincola FM and Ferrone S: HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5: 178-186, 1999.
5. Sharpe AH and Freeman GJ: The B7-CD28 superfamily. Nat Rev Immunol 2: 116-126, 2002.
6. Kim R, Emi M, Tanabe K and Arihiro K: Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66: 5527-5536, 2006.
7. Hellstrom KE and Hellstrom I: Novel approaches to therapeutic cancer vaccines. Expert Rev Vaccines 2: 517-532, 2003.
8. Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME, Sakaguchi S and Houghton AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200: 771-782, 2004.
9. Chen L, Linsley PS and Hellstrom KE: Costimulation of T cells for tumor immunity. Immunol Today 14: 483-486, 1993.
10. June CH, Ledbetter JA, Linsley PS and Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 11: 211-216, 1990.
11. Fraser JD, Irving BA, Crabtree GR and Weiss A: Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251: 313-316, 1991.
12. Jenkins MK, Taylor PS, Norton SD and Urdahl KB: CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 147: 2461-2466, 1991.
13. Lenschow DJ, Walunas TL and Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258, 1996.
14. Zambricki E, Shigeoka A, Kishimoto H, Sprent J, Burakoff S, Carpenter C, Milford E and McKay D: Signaling T-cell survival and death by IL-2 and IL-15. Am J Transplant 5: 2623-2631, 2005.
15. Tibaldi EV, Salgia R and Reinherz EL: CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillance. Proc Natl Acad Sci USA 99: 7582-7587, 2002.
16. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS and Siahaan TJ: Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 22: 146-167, 2002.
17. Gaffen SL: Signaling domains of the interleukin 2 receptor. Cytokine 14: 63-77, 2001.
18. Maes BD and Vanrenterghem YF: Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation. Nephrol Dial Transplant 14: 2824-2826, 1999.
19. Demaison C, Chastagner P, Moreau JL and Theze J: Ligand-induced autoregulation of IL-2 receptor alpha chain expression in murine T cell lines. Int Immunol 8: 1521-1528, 1996.
20. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M and Schirrmacher V: Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 119: 328-338, 2006.
21. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R and Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6: 63-73, 1999.
22. Washburn B and Schirrmacher V: Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 21: 85-93, 2002.
23. Ertel C, Millar NS, Emmerson PT, Schirrmacher V and von Hoegen P: Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur J Immunol 23: 2592-2596, 1993.
24. Haas C, Lulei M, Fournier P, Arnold A and Schirrmacher V: T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine 23: 2439-2453, 2005.
25. Bian H, Fournier P, Moormann R, Peeters B and Schirrmacher V: Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther 12: 295-303, 2005.
26. Kufer P, Zettl F, Borschert K, Lutterbuse R, Kischel R and Riethmuller G: Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immun 1: 10, 2001.
27. Mann M, Ong SE, Gronborg M, Steen H, Jensen ON and Pandey A: Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol 20: 261-268, 2002. (Pubitemid 34451062)
28. Steen H, Pandey A, Andersen JS and Mann M: Analysis of tyrosine phosphorylation sites in signaling molecules by a phosphotyrosine-specific immonium ion scanning method. Sci STKE. PL16, 2002.
29. Geng L and Rudd CE: Signalling scaffolds and adaptors in T-cell immunity. Br J Haematol 116: 19-27, 2002.
30. Wange RL: LAT, the linker for activation of T cells: a bridge between T cell-specific and general signaling pathways. Sci STKE 2000: 63, 2000.
31. Braiman A, Barda-Saad M, Sommers CL and Samelson LE: Recruitment and activation of PLCgamma1 in T cells: a new insight into old domains. EMBO J 25: 774-784, 2006.
32. Hatakeyama M, Kono T, Kobayashi N, Kawahara A, Levin SD, Perlmutter RM and Taniguchi T: Interaction of the IL-2 receptor with the src-family kinase p56lck: identification of novel intermolecular association. Science 252: 1523-1528, 1991.
33. Tigges MA, Casey LS and Koshland ME: Mechanism of interleukin-2 signaling: mediation of different outcomes by a single receptor and transduction pathway. Science 243: 781-786, 1989.
34. Ardouin L, Bracke M, Mathiot A, Pagakis SN, Norton T, Hogg N and Tybulewicz VL: Vav1 transduces TCR signals required for LFA-1 function and cell polarization at the immunological synapse. Eur J Immunol 33: 790-797, 2003.
35. Visse E, Inostroza J, Cabello G and Parra E: The MAP kinases are differently utilized by CD28 and CD2 adhesion pathways in superantigen-activated Jurkat T cells. Biol Res 36: 263-278, 2003.
36. Su B, Cheng J, Yang J and Guo Z: MEKK2 is required for T-cell receptor signals in JNK activation and interleukin-2 gene expression. J Biol Chem 276: 14784-14790, 2001.
37. Minden A, Lin A, Claret FX, Abo A and Karin M: Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81: 1147-1157, 1995.
38. Sallusto F, Geginat J and Lanzavecchia A: Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763, 2004.
39. Reedquist KA, Fukazawa T, Druker B, Panchamoorthy G, Shoelson SE and Band H: Rapid T-cell receptor-mediated tyrosine phosphorylation of p120, an Fyn/Lck Src homology 3 domain-binding protein. Proc Natl Acad Sci USA 91: 4135-4139, 1994.
40. Yashiro Y, Tai XG, Toyo-oka K, Park CS, Abe R, Hamaoka T, Kobayashi M, Neben S and Fujiwara H: A fundamental difference in the capacity to induce proliferation of naive T cells between CD28 and other co-stimulatory molecules. Eur J Immunol 28: 926-935, 1998.
41. Akbar AN, Borthwick NJ, Wickremasinghe RG, Panayoitidis P, Pilling D, Bofill M, Krajewski S, Reed JC and Salmon M: Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bclxL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol 26: 294-299, 1996.
42. D'Souza WN and Lefrançois L: IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol 171: 5727-5735, 2003.
43. Parra E, Varga M, Hedlund G, Kalland T and Dohlsten M: Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT DNA binding. Mol Cell Biol 17: 1314-1323, 1997.
44. Jain J, Valge-Archer VE, Sinskey AJ and Rao A: The AP-1 site at -150 bp, but not the NF-kappa B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter. J Exp Med 175: 853-862, 1992.
45. Zhou XY, Yashiro-Ohtani Y, Nakahira M, Park WR, Abe R, Hamaoka T, Naramura M, Gu H and Fujiwara H: Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J Immunol 168: 3847-3854, 2002.
46. Thomas RM, Gao L and Wells AD: Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J Immunol 174: 4639-4646, 2005.
47. Termeer CC, Schirrmacher V, Brocker EB and Becker JC: Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 7: 316-323, 2000.
48. Puhlmann J, Puehler F, Mumberg D, Boukamp P and Beier R: Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 29: 2205-2216, 2010.
49. Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, Ponugoti A, Nabioullin R, Deroo S, Yang S, Wang X, McGrath JP, Protopopova M, Ivanova E, Zhang J, Feng B, Tsao MS, Redston M, Protopopov A, Xiao Y, Futreal PA, Hahn WC, Klimstra DS, Chin L and De Pinho RA: Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci USA 105: 19372-19377, 2008.
50. Schirrmacher V and Fournier P: Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol 542: 565-605, 2009.
51. Samelson LE: Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol 20: 371-394, 2002.